ClinicalTrials.gg
CompletedNCT06845813Updated Nov 3, 2025

Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234

A Phase 1 interventional study of AZD6234 in Renal Impairment, sponsored by AstraZeneca. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
15th of 29
24 · median 24
Started
2025
with 1 other
Phase 1
26 of 29
none open now
Registered
27th of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 15th largest by enrollment, is one of 2 that started in 2025, is one of 26 in phase 1, and was the 27th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of single subcutaneous dose of AZD6234 with end stage renal disease, severe, and possibly moderate and mild renal impairment in comparison to a matched healthy control group.

Read the detailed description

This Phase I multicentre, single-dose, non-randomised, open-label, parallel-group study aims to examine the pharmacokinetics, safety, and tolerability of AZD6234 in both male and female participants. Participants include those with end-stage renal disease (ESRD) on intermittent haemodialysis (HD), severe renal impairment not on dialysis, and optional groups for moderate and mild renal impairment. These are compared to participants with normal renal function. All participants are grouped based on body surface area-adjusted estimated glomerular filtration rate (eGFR), and those with normal renal function are matched at a group level by sex, age, and body mass index (BMI) to the participants with impaired renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Renal Impairment
  • Healthy Participants
  • AZD6234
  • Pharmacokinetics
  • Safety
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 85 years of age, inclusive, at the time of signing the .
  • Body weight ≥ 50 kg; within the range of ≥ 18 to ≤ 40 kg/m2, as measured at screening.

Healthy Matched Control Participants:

  • Participant must be medically healthy with no medical history, or abnormalities in physical examination, clinical laboratory profiles, vital signs, or 12-lead ECGs, as deemed by the investigator at screening and Day -1.
  • Have an of ≥ 90 mL/min determined at screening.

Renally-impaired Participants:

  • Diagnosis of chronic kidney disease, stable renal function in the 3 months prior to dosing,
  • Participants with renal impairment based on BSA-adjusted CKD-EPI equation at screening.
  • All renally-impaired participants should be on a stable dose of cardio-renal relevant treatment for at least 2 weeks prior to screening.
  • If participants with renal impairment have diabetes mellitus, it must be controlled
  • Female(s) of : must use adequate . Oral contraceptives are not permitted as there is a potential effect of the IMP on the absorption of oral drugs.
  • Male Participants: Condom use is required for the duration of the study and until at least 28 days after the last dose of IMP. Additional contraception must be used for the sexual partners of male study participants throughout the clinical trial and for 28 days following the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

- History or presence of: significant GI disease or previous upper GI surgery

  • cardiovascular disease, as judged by the investigator, d. Neuromuscular or neurogenic disease e. Severe vitamin D deficiency \< 12 ng/dL.
  • History or presence of any condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  • History of psychosis, bipolar disorder
  • History of major depressive disorder within the past 2 years
  • History of suicide attempt or history of suicidal ideation within the past year.

Healthy Matched Control Participants:

  • History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • Use of any prescription or non-prescription drugs, unless, in the opinion of the investigator and sponsor, the medication will not interfere with the study.

Renally-impaired Participants:

  • Presence of unstable medical condition or any evidence of additional severe or uncontrolled systemic disease or laboratory finding which, in the opinion of the investigator, would compromise the participant's safety or successful participation in this study.
  • Renal transplant patients, participants waiting for organ transplant scheduled to occur during the study, and those with a history of acute kidney injury occurring within 3 months prior to screening. Nonfunctioning renal allografts are allowed.
  • Use of concurrent medication which affects calculation of by affecting serum creatinine within 7 days of Day -1.
  • Unable to refrain from phosphate binders, cholestyramine/colestipol, and ranitidine/nizatidine within 10 hours before and 10 hours after study intervention.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1

    Subjects with end stage renal disease will receive a single subcutaneous dose of AZD6234 under fasted conditions

    Drug: AZD6234

  • Experimental
    Group 2

    Subjects with severe renal impairment will receive a single subcutaneous dose of AZD6234 under fasted conditions

    Drug: AZD6234

  • Experimental
    Group 3

    Healthy participants will receive a single subcutaneous dose of AZD6234 under fasted conditions

    Drug: AZD6234

  • Experimental
    Group 4 (optional)

    Subjects with moderate renal impairment will receive a single subcutaneous dose of AZD6234 under fasted conditions

    Drug: AZD6234

  • Experimental
    Group 5 (optional)

    Subjects with mild renal impairment will receive a single subcutaneous dose of AZD6234 under fasted conditions

    Drug: AZD6234

Interventions

  • Dose 1

    Also known as: Dose 1

06

What researchers measure

Primary outcomes

  1. AUClast

    Area under plasma concentration-time curve from time zero to the last measurable concentration

    Time frame: Day 1 to Day 36

  2. AUCinf

    Area under plasma concentration-time curve from zero to infinity

    Time frame: Day 1 to Day 36

  3. Cmax

    Maximum observed plasma concentration

    Time frame: Day 1 to Day 36

Secondary outcomes

  1. Tmax

    Time to reach maximum observed plasma concentration

    Time frame: Day 1 to Day 36

  2. PK parameter (t1/2λz)

    Terminal elimination half-life

    Time frame: Day 1 to Day 36

  3. PK parameter (CL/F)

    Apparent plasma clearance

    Time frame: Day 1 to Day 36

  4. PK parameter (Vz/F)

    Apparent volume of distribution during the terminal phase

    Time frame: Day 1 to Day 36

  5. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of a single subcutaneous dose of AZD6234 in participants with end stage renal disease, severe, moderate (optional), and mild (optional) renal impairment and those with normal renal function.

    Time frame: Day 1 to Day 54

  6. Number of participants with abnormal vital signs

    To assess the safety and tolerability of a single subcutaneous dose of AZD6234 in participants with end stage renal disease, severe, moderate (optional), and mild (optional) renal impairment and those with normal renal function.

    Time frame: Day 1 to Day 54

  7. Number of participants with abnormal ECGs

    To assess the safety and tolerability of a single subcutaneous dose of AZD6234 in participants with end stage renal disease, severe, moderate (optional), and mild (optional) renal impairment and those with normal renal function.

    Time frame: Day 1 to Day 54

  8. Number of participants with abnormal physical examination findings

    To assess the safety and tolerability of a single subcutaneous dose of AZD6234 in participants with end stage renal disease, severe, moderate (optional), and mild (optional) renal impairment and those with normal renal function.

    Time frame: Day 1 to Day 54

  9. Number of participants with abnormal laboratory test results

    To assess the safety and tolerability of a single subcutaneous dose of AZD6234 in participants with end stage renal disease, severe, moderate (optional), and mild (optional) renal impairment and those with normal renal function.

    Time frame: Day 1 to Day 54

  10. Number of participants with confirmed positive anti-drug antibody testing

    Prevalence and incidence of ADAs to AZD6234 ADA titre

    Time frame: Day 1 to Day 54

  11. Number of participants with serious adverse events (SAEs)

    To assess the safety and tolerability of a single subcutaneous dose of AZD6234 in participants with end stage renal disease, severe, moderate (optional), and mild (optional) renal impairment and those with normal renal function.

    Time frame: Day 1 to Day 54

07

Study locations

3 sites
  • Research Site
    Lake Forest, California 92630, United States
  • Research Site
    Orlando, Florida 32808, United States
  • Research Site
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2025, 7 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Feb 25, 2025
StartActual
Feb 24, 2025
Primary completionActual
Sep 30, 2025
CompletionActual
Sep 30, 2025
Last update
Nov 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06845813
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 25, 2025
Start date
Feb 24, 2025
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Last update
Nov 3, 2025

Study contacts

Fadi Saba, M.D.
principal investigator · Servico Integrado de Tecnicas Endovasculares
Thomas C Marbury, M.D.
principal investigator · Servico Integrado de Tecnicas Endovasculares
Joel M Neutel, M.D.
principal investigator · Servico Integrado de Tecnicas Endovasculares
Kwabena Ayesu, M.D.
principal investigator · Servico Integrado de Tecnicas Endovasculares

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6234

Start the discussion